0%
0%
0%
0%
0%
About Evolus, Inc. Common Stock
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David Moatazedi
Website
evolus.com
Headquarters
Newport Beach
Employees
215
Founded
2012
ISIN
US30052C1071
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
EOLS looking decent.. lots of eyes on it too though.. and a couple of the other names in group enph.. look good.. put some of the others pulled back.
EOLS - Speculative opportunity 3:1Coming out of a 3 month consolidation. Volume extremely light on the latest pullback, signs of supply has dried up.
You don't need to know what's going to happen next to make money ~Mark Douglas
Lose like a pro and keep trading, or lose like a novice and quit ~Mark Ritchie
EOLS BreakoutAfter a ~500% run this year EOLS settled down and found gap support at $8.25. It has since put in a cup w/ handle pattern from which it broke today. The volume today is well above average and should be a signal that this breakout should hold if the market wants to cooperate. I went long this morning
EOLS: Bullish FlagBullish Flag
Pros:
Descending volume during formation
PPS above 50MA and 200MA
Golden cross in blue
RS above 0, and ascending
ATR Ascending
R/R ratio above 4
250RSI above 50
200MA ascending
Cons:
Gap dowm may get filled anytime.
Target:
PT = 18.29$
1000 Followers! Thank you all!
Thank you to thos
$EOLS skyrocketed after end of Intellectual Property LitigationAbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
